Treatment of steroid refractory acute and chronic graft‐versus‐host disease with daclizumab
- 1 March 2001
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 112 (3) , 820-823
- https://doi.org/10.1046/j.1365-2141.2001.02582.x
Abstract
Competitive inhibition of interleukin 2‐dependent lymphocytes by daclizumab demonstrates some beneficial effects in the treatment of graft‐versus‐host disease (GVHD). Sixteen patients with steroid refractory GVHD received daclizumab (1 mg/kg BW) on d 1, 2 (−5), 7, 14 and 21. Twelve patients suffered from grade III–IV acute GVHD and four patients from extensive chronic GVHD. Responses were observed in nine patients (six acute, three chronic GVHD). Fourteen out of 16 patients acquired infections during daclizumab treatment and three deaths were infection related. Daclizumab demonstrates limited activity and is associated with an increased incidence of infectious complications.Keywords
This publication has 10 references indexed in Scilit:
- Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host diseaseBlood, 2000
- CYTOMEGALOVIRUS INFECTIONS AFTER TREATMENT WITH DACLIZUMAB, AN ANTI IL-2 RECEPTOR ANTIBODY, FOR PREVENTION OF RENAL ALLOGRAFT REJECTIONTransplantation, 1999
- A randomized prospective study comparing low-dose 0KT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipientsTransplant International, 1998
- A PROSPECTIVE RANDOMIZED TRIAL COMPARING INTERLEUKIN-2 RECEPTOR ANTIBODY VERSUS ANTITHYMOCYTE GLOBULIN AS PART OF A QUADRUPLE IMMUNOSUPPRESSIVE INDUCTION THERAPY FOLLOWING ORTHOTOPIC LIVER TRANSPLANTATIONTransplantation, 1997
- A low incidence of grade II to IV acute GVHD, but high mortality from infection using HLA-A, -B, and -DR-identical unrelated donors and immunosuppression with ATG, cyclosporine, and methotrexateTransplantation Proceedings, 1997
- The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisoneBlood, 1995
- Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxisThe Lancet, 1995
- Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptorBlood, 1994
- What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants?Blood, 1990
- Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcomeBlood, 1990